Multiple Myeloma, Version 1.2013

Anderson, Kenneth C.; Alsina, Melissa; Bensinger, William I.; Biermann, J. Sybil; Cohen, Adam D.; Devine, Steven M.; Djulbegoviĉ, Benjamin; Faber, Edward A.; Gasparetto, Cristina; Hernandez-Illizaliturri, Francisco J.; Huff, Carol Ann; Kassim, Adetola A.; Krishnan, Amrita; Liedtke, Michael; Meredith, Ruby F.; Raje, Noopur; Schriber, Jeffrey; Singhal, Seema; Somlo, George; Stockerl-Goldstein, Keith; Treon, Steven P.; Weber, Donna M.; Yahalom, Joachim; Yunus, Furhan; Shead, Dorothy A.; Kumar, Rashmi

doi:10.6004/jnccn.2013.0004

Cited by 62 publications

(43 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Most guidelines, however, recommend ASCT1 as upfront consolidation treatment. [22][23][24] Our PBSC collection and storage practices are likely a reflection of the change in treatment paradigms with time as novel immunomodulatory agents, and proteasome inhibitors became available. We observed a decreasing trend in the frequencies of second ASCTs over the past decade, from 24% in the period 2004 and 2007 to 9% in the period 2008 and 2011.…”

Section: Resultsmentioning

confidence: 99%

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

Phipps

Linenberger

Holmberg

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many centers routinely collect and store adequate PBSCs for two ASCTs. We analyzed the cost associated with this practice by determining the expenses of PBSC collection, cryopreservation and storage, and the ultimate use of additional cryopreserved PBSCs in patients who had undergone at least one ASCT. There were 889 MM patients transplanted between 1993 and 2011 at our center. Most (N=726) had residual PBSCs in storage after their first ASCT (ASCT1). Only 135 patients underwent a second ASCT within a median of 14 months after ASCT1. The percentage of patients receiving a second ASCT declined over time. The resources required to collect and store unused PBSCs added up to 336 extra patient days of apheresis and 41 587 extra patient months of cryopreservation, translating into an average extra cost per patient of US$4981.12. A reconsideration of conventional PBSC collection and storage practices would save significant cost for the majority of MM patients who never undergo a second ASCT.

show abstract

Section: Resultsmentioning

confidence: 99%

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

Phipps

Linenberger

Holmberg

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…These recommendations are based on personal experience and anchored, when possible, on clinical evidence and not meant for comprehensive care of the newly diagnosed MM patient, but rather focused on the avoidance of early complications. Multiple other review articles and consensus statements can provide assistance on the choice of initial or subsequent therapies [15,[19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

et al. 2015

View full text Add to dashboard Cite

In the era of novel biological agents, multiple myeloma (MM) is often approached as a chronic condition. While survival continues to improve, population‐level data indicate that early mortality remains a substantial barrier to advances in MM outcomes. Here we provide “do's and don'ts” management recommendations that may minimize the risk of early mortality and ensure that patients have the opportunity to benefit from the long term impact of new effective MM agents. Such recommendations encompass the early introduction of novel agents even in the presence of comorbidities and advanced age and aggressive management of MM‐related complications. Am. J. Hematol. 91:101–108, 2016. © 2015 Wiley Periodicals, Inc.

show abstract

“…In addition, bortezomibbased therapies have been incorporated into the front-line setting for patients with newly diagnosed myeloma (4 -7) and are being considered in other settings as well, including as part of maintenance therapy (8). Indeed, together with other advances, such as the development of immunomodulatory agents, bortezomib has contributed to a doubling in the overall survival of myeloma patients over the last decade (9 -12).…”

mentioning

confidence: 99%

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

Chen

et al. 2015

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Acquired proteasome inhibitor resistance emerges in myeloma patients through incompletely understood mechanisms. Results: Activation of nuclear factor (erythroid-derived 2)-like 2 (NRF2) and proteassemblin (POMP) was linked to bortezomib resistance, while their inhibition reversed resistance. Conclusion:The NRF2/POMP axis contributes to bortezomib resistance. Significance: NRF2/POMP axis inhibition can be translated to the clinic to reverse bortezomib resistance and induce chemosensitization.

show abstract

Multiple Myeloma, Version 1.2013

Cited by 62 publications

References 20 publications

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy

Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

Contact Info

Product

Resources

About